Skip to content

Patient Activation, Counseling and Exercise - Acute Leukemia (PACE-AL)

Patient Activation, Counseling and Exercise - Acute Leukemia (PACE-AL) Health Promoting Rehabilitation. A Multimodal Exercise-based Intervention in Patients With Acute Leukaemia Undergoing Re-induction or Consolidation Chemotherapy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01404520
Acronym
PACE-AL
Enrollment
70
Registered
2011-07-28
Start date
2011-06-30
Completion date
2015-05-31
Last updated
2015-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Leukemia

Keywords

#14 Cancer Related fatigue, #13 Quality of Life, #12 Psychosocial Intervention[ti/ab], #11 Rehabilitation[tw], #10 Physical Fitness[tw], #9 Physical Activity[tw], #8 Exercise Therapy[tw], #7 Exercise[tw], #6 Hematologic[tw], #5 Hematological[tw], #4 Leukemia, Myeloid, Acute[mh], #3 Acute Myeloid Leukemia[tw], #2 Acute Lymphoblastic Leukemia[tw], #1 Acute Leukemia[tw]

Brief summary

The purpose of this study is to test a new preventive and restorative intervention for patients with acute leukaemia undergoing consolidation chemotherapy, to measure and delineate the patients' treatment related symptom burden and to explore the effect of the intervention on length of hospital stay, duration of sick leave and return to work status. Further, to examine the relationship of the symptom profile with clinical indicators, physiological response, physical performance and survival.

Interventions

OTHERExercise based multimodal intervention

The intervention is initiated early, during treatment (consolidation) in the intra-hospital setting and continues for two successive treatment series (12 weeks). The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and health-promoting consultation combined with an unsupervised in-home walking and progressive relaxation programme.

Sponsors

University of Copenhagen
CollaboratorOTHER
Novo Nordisk A/S
CollaboratorINDUSTRY
Danish Cancer Society
CollaboratorOTHER
Lundbeck Foundation
CollaboratorOTHER
Universitetshospitalernes Center for Sygepleje
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients that are able to speak Danish \> 18 years and newly diagnosed with acute leukæmia (MDS, AML, CMML, APL or ALL) * Normal EKG, blood pressure and pulse * Signed informed written consent

Exclusion criteria

* Medical reason that contraindicates physical activity * Patients diagnosed with a symptomatic cardial disease * Documented bone metastasis * Cognitively or emotionally unstable * Unable to read or write in Danish * Patients unable to carry out baseline tests

Design outcomes

Primary

MeasureTime frameDescription
Six Minute Walk Distance 6MWDChange from baseline in 6MWD at 12 weeksChange in distance in meter

Secondary

MeasureTime frameDescription
Timed chair standChange from baseline in timed chair stand at 12 weeksChange in number of repetitions
Timed biceps curlChange from baseline in timed bicep curl at 12 weeksChange in number of repetitions
EORTC QLQ-C30Change from baseline in EORTC QLQ-C30 at 12 weeksChange in scores for quality of life
Estimated VO2 max Aastrand testChange from baseline in VO2 Aastrand test at 12 weeksChange in l/m
HADSChange from baseline in HADS at 12 weeksChange in scores for emotional wellbeing
SF36Change from baseline in SF36 at 12 weeksChange in scores for general health
MDASIChange from baseline over time (1,2,3,4,5,6,7,8,9,10,11,12 weeks)Change in scores for symptom burden
FACT-AnChange from baseline in FACT-An at 12 weeksChange in scores for quality of life/function

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 22, 2026